HCR Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

HCR Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-286	Closed	-$221K	–	257
2025 Q4	$221K	Buy	+286	New	+$194K	0.02%	231
2024 Q4	–	Sell	-277	Closed	-$291K	–	237
2024 Q3	$291K	Hold	277	–	–	0.04%	180
2024 Q2	$291K	Hold	277	–	–	0.04%	176
2024 Q1	$267K	Sell	277 -5	-2%	-$4.75K	0.04%	181
2023 Q4	$248K	Buy	282 +37	+15%	+$30.5K	0.04%	171
2023 Q3	$202K	Buy	+245	New	+$193K	0.04%	163
2023 Q2	–	Sell	-250	Closed	-$205K	–	183
2023 Q1	$205K	Buy	+250	New	+$189K	0.04%	164
2022 Q2	–	Sell	-310	Closed	-$217K	–	195
2022 Q1	$217K	Buy	+310	New	+$196K	0.04%	176
2020 Q4	–	Sell	-408	Closed	-$228K	–	275
2020 Q3	$228K	Buy	+408	New	+$247K	0.05%	149

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HCR Wealth Advisors's REGN Position: Q1 2026 in Review

HCR Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 286 shares — an estimated $221K sold.

HCR Wealth Advisors first reported a position in REGN in Q3 2020 and held it in 9 quarters. The position peaked at $291K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

HCR Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
HCR Wealth Advisors sold 286 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $221K.
HCR Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 9 quarters.
HCR Wealth Advisors's Regeneron Pharmaceuticals position peaked at $291K in Q3 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on HCR Wealth Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.